PCSK9 and familial hypercholesterolemia: Monoclonal anti-PCSK9 neutralizing antibodies are currently used for a potent reduction of the LDLc levels by 50–60% and are indicated for patients with familial hypercholesterolemia or those who are statin-intolerant who need cardiovascular prevention.